QQQ na na (na)
DIA na na (na)
SPY na na (na)
TLT na na (na)
GLD na na (na)
$ na
-- x --
-- x --
-- - --
na - na
0
na
na
na
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3GAITHERSBURG, Md., Ju...

 jim-cramer-says-hes-going-to-have-to-wait-on-sofi-but-recommends-this-great-little-industrial-company

Jim Cramer can't recommend Twilio due to recent stock downgrade. He prefers Vistra Corp. and Constellation Energy Corp. for...

Core News & Articles

- Reuters

 novavax-submits-amendment-to-fda-for-emergency-use-authorization-of-updated-jn1-covid-19-vaccine-for-ages-12-and-older-targets-jn1-lineage-following-guidance-from-fda-ema-and-who

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3Novavax's...

 b-of-a-securities-maintains-neutral-on-novavax-raises-price-target-to-18

B of A Securities analyst Alec Stranahan maintains Novavax (NASDAQ:NVAX) with a Neutral and raises the price target from $12...

Core News & Articles

-Reuters

 novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.